Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil

Detalhes bibliográficos
Autor(a) principal: Hungria,Emerith Mayra
Data de Publicação: 2012
Outros Autores: Oliveira,Regiane Morillas de, Souza,Ana Lúcia Osório Maroclo de, Costa,Maurício Barcelos, Souza,Vânia Nieto Brito de, Silva,Eliane Aparecida, Moreno,Fátima Regina Vilani, Nogueira,Maria Esther Salles, Costa,Maria Renata Sales Nogueira, Silva,Sônia Maria Usó Ruiz, Bührer-Sékula,Samira, Reed,Steven G, Duthie,Malcolm S, Stefani,Mariane Martins de Araújo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Memórias do Instituto Oswaldo Cruz
Texto Completo: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000900017
Resumo: New Mycobacterium leprae protein antigens can contribute to improved serologic tests for leprosy diagnosis/classification and multidrug therapy (MDT) monitoring. This study describes seroreactivity to M. leprae proteins among participants from three highly endemic leprosy areas in Brazil: central-western Goiânia/Goiás (GO) (n = 225), Rondonópolis/Mato Grosso (MT) (n = 764) and northern Prata Village/Pará (PA) (n = 93). ELISA was performed to detect IgG to proteins (92f, 46f, leprosy IDRI diagnostic-1, ML0405, ML1213) and IgM to phenolic glycolipid-I (PGL-I). Multibacillary (MB) leprosy had positive rates for PGL-I that were similar to those for proteins; however, some anti-PGL-I-negative subjects were positive for proteins, suggesting that adding protein antigen to PGL-I can enhance the sensitivity of MB leprosy detection. In MT, different degrees of seroreactivity were observed and ranked for MB, former patients after MDT, paucibacillary (PB) leprosy, household contact (HHC) and endemic control (EC) groups. The seroreactivity of PB patients was low in GO and MT. HHCs from different endemic sites had similar IgG antibody responses to proteins. 46f and 92f were not recognised by most tuberculosis patients, ECs or HHCs within GO, an area with high BCG vaccination coverage. Low positivity in EC and HHC was observed in PA and MT. Our results provide evidence for the development of an improved serologic test that could be widely applicable for MB leprosy testing in Brazil.
id FIOCRUZ-4_904f5db60a3a8109ba3dd82cc1f5f936
oai_identifier_str oai:scielo:S0074-02762012000900017
network_acronym_str FIOCRUZ-4
network_name_str Memórias do Instituto Oswaldo Cruz
spelling Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in BrazilleprosydiagnosisserologyNew Mycobacterium leprae protein antigens can contribute to improved serologic tests for leprosy diagnosis/classification and multidrug therapy (MDT) monitoring. This study describes seroreactivity to M. leprae proteins among participants from three highly endemic leprosy areas in Brazil: central-western Goiânia/Goiás (GO) (n = 225), Rondonópolis/Mato Grosso (MT) (n = 764) and northern Prata Village/Pará (PA) (n = 93). ELISA was performed to detect IgG to proteins (92f, 46f, leprosy IDRI diagnostic-1, ML0405, ML1213) and IgM to phenolic glycolipid-I (PGL-I). Multibacillary (MB) leprosy had positive rates for PGL-I that were similar to those for proteins; however, some anti-PGL-I-negative subjects were positive for proteins, suggesting that adding protein antigen to PGL-I can enhance the sensitivity of MB leprosy detection. In MT, different degrees of seroreactivity were observed and ranked for MB, former patients after MDT, paucibacillary (PB) leprosy, household contact (HHC) and endemic control (EC) groups. The seroreactivity of PB patients was low in GO and MT. HHCs from different endemic sites had similar IgG antibody responses to proteins. 46f and 92f were not recognised by most tuberculosis patients, ECs or HHCs within GO, an area with high BCG vaccination coverage. Low positivity in EC and HHC was observed in PA and MT. Our results provide evidence for the development of an improved serologic test that could be widely applicable for MB leprosy testing in Brazil.Instituto Oswaldo Cruz, Ministério da Saúde2012-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000900017Memórias do Instituto Oswaldo Cruz v.107 suppl.1 2012reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/S0074-02762012000900017info:eu-repo/semantics/openAccessHungria,Emerith MayraOliveira,Regiane Morillas deSouza,Ana Lúcia Osório Maroclo deCosta,Maurício BarcelosSouza,Vânia Nieto Brito deSilva,Eliane AparecidaMoreno,Fátima Regina VilaniNogueira,Maria Esther SallesCosta,Maria Renata Sales NogueiraSilva,Sônia Maria Usó RuizBührer-Sékula,SamiraReed,Steven GDuthie,Malcolm SStefani,Mariane Martins de Araújoeng2020-04-25T17:51:21Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:18:44.376Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue
dc.title.none.fl_str_mv Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil
title Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil
spellingShingle Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil
Hungria,Emerith Mayra
leprosy
diagnosis
serology
title_short Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil
title_full Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil
title_fullStr Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil
title_full_unstemmed Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil
title_sort Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil
author Hungria,Emerith Mayra
author_facet Hungria,Emerith Mayra
Oliveira,Regiane Morillas de
Souza,Ana Lúcia Osório Maroclo de
Costa,Maurício Barcelos
Souza,Vânia Nieto Brito de
Silva,Eliane Aparecida
Moreno,Fátima Regina Vilani
Nogueira,Maria Esther Salles
Costa,Maria Renata Sales Nogueira
Silva,Sônia Maria Usó Ruiz
Bührer-Sékula,Samira
Reed,Steven G
Duthie,Malcolm S
Stefani,Mariane Martins de Araújo
author_role author
author2 Oliveira,Regiane Morillas de
Souza,Ana Lúcia Osório Maroclo de
Costa,Maurício Barcelos
Souza,Vânia Nieto Brito de
Silva,Eliane Aparecida
Moreno,Fátima Regina Vilani
Nogueira,Maria Esther Salles
Costa,Maria Renata Sales Nogueira
Silva,Sônia Maria Usó Ruiz
Bührer-Sékula,Samira
Reed,Steven G
Duthie,Malcolm S
Stefani,Mariane Martins de Araújo
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Hungria,Emerith Mayra
Oliveira,Regiane Morillas de
Souza,Ana Lúcia Osório Maroclo de
Costa,Maurício Barcelos
Souza,Vânia Nieto Brito de
Silva,Eliane Aparecida
Moreno,Fátima Regina Vilani
Nogueira,Maria Esther Salles
Costa,Maria Renata Sales Nogueira
Silva,Sônia Maria Usó Ruiz
Bührer-Sékula,Samira
Reed,Steven G
Duthie,Malcolm S
Stefani,Mariane Martins de Araújo
dc.subject.por.fl_str_mv leprosy
diagnosis
serology
topic leprosy
diagnosis
serology
dc.description.none.fl_txt_mv New Mycobacterium leprae protein antigens can contribute to improved serologic tests for leprosy diagnosis/classification and multidrug therapy (MDT) monitoring. This study describes seroreactivity to M. leprae proteins among participants from three highly endemic leprosy areas in Brazil: central-western Goiânia/Goiás (GO) (n = 225), Rondonópolis/Mato Grosso (MT) (n = 764) and northern Prata Village/Pará (PA) (n = 93). ELISA was performed to detect IgG to proteins (92f, 46f, leprosy IDRI diagnostic-1, ML0405, ML1213) and IgM to phenolic glycolipid-I (PGL-I). Multibacillary (MB) leprosy had positive rates for PGL-I that were similar to those for proteins; however, some anti-PGL-I-negative subjects were positive for proteins, suggesting that adding protein antigen to PGL-I can enhance the sensitivity of MB leprosy detection. In MT, different degrees of seroreactivity were observed and ranked for MB, former patients after MDT, paucibacillary (PB) leprosy, household contact (HHC) and endemic control (EC) groups. The seroreactivity of PB patients was low in GO and MT. HHCs from different endemic sites had similar IgG antibody responses to proteins. 46f and 92f were not recognised by most tuberculosis patients, ECs or HHCs within GO, an area with high BCG vaccination coverage. Low positivity in EC and HHC was observed in PA and MT. Our results provide evidence for the development of an improved serologic test that could be widely applicable for MB leprosy testing in Brazil.
description New Mycobacterium leprae protein antigens can contribute to improved serologic tests for leprosy diagnosis/classification and multidrug therapy (MDT) monitoring. This study describes seroreactivity to M. leprae proteins among participants from three highly endemic leprosy areas in Brazil: central-western Goiânia/Goiás (GO) (n = 225), Rondonópolis/Mato Grosso (MT) (n = 764) and northern Prata Village/Pará (PA) (n = 93). ELISA was performed to detect IgG to proteins (92f, 46f, leprosy IDRI diagnostic-1, ML0405, ML1213) and IgM to phenolic glycolipid-I (PGL-I). Multibacillary (MB) leprosy had positive rates for PGL-I that were similar to those for proteins; however, some anti-PGL-I-negative subjects were positive for proteins, suggesting that adding protein antigen to PGL-I can enhance the sensitivity of MB leprosy detection. In MT, different degrees of seroreactivity were observed and ranked for MB, former patients after MDT, paucibacillary (PB) leprosy, household contact (HHC) and endemic control (EC) groups. The seroreactivity of PB patients was low in GO and MT. HHCs from different endemic sites had similar IgG antibody responses to proteins. 46f and 92f were not recognised by most tuberculosis patients, ECs or HHCs within GO, an area with high BCG vaccination coverage. Low positivity in EC and HHC was observed in PA and MT. Our results provide evidence for the development of an improved serologic test that could be widely applicable for MB leprosy testing in Brazil.
publishDate 2012
dc.date.none.fl_str_mv 2012-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000900017
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000900017
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0074-02762012000900017
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
dc.source.none.fl_str_mv Memórias do Instituto Oswaldo Cruz v.107 suppl.1 2012
reponame:Memórias do Instituto Oswaldo Cruz
instname:Fundação Oswaldo Cruz
instacron:FIOCRUZ
reponame_str Memórias do Instituto Oswaldo Cruz
collection Memórias do Instituto Oswaldo Cruz
instname_str Fundação Oswaldo Cruz
instacron_str FIOCRUZ
institution FIOCRUZ
repository.name.fl_str_mv Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz
repository.mail.fl_str_mv
_version_ 1669937713015422976